{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-24-000052","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.986465+00:00","generated_at":"2026-06-04T06:34:04.732747+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Centessa reports Q4 net loss $36.8M; cash $256.5M; SerpinPC and ORX750 milestones on track","bullets":["Net loss of $36.8M for Q4 2023 vs $43.2M YoY; full-year net loss $151.1M vs $216.2M.","Cash, equivalents and ST investments $256.5M at Dec 31, 2023; plus $9.7M ATM proceeds in Jan 2024; funding into 2026.","SerpinPC PRESent-2 Part 1 interim analysis planned in 2024; Part 1 data at medical conference late 2024/early 2025.","ORX750 IND clearance targeted; clinical proof-of-concept data in sleep-deprived healthy volunteers expected in 2024.","Phase 2a SerpinPC data showed 96% median all-bleed ABR reduction with no thromboembolic events to date."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-24-000052","json":"https://secwatch.observer/filing/0001847903-24-000052.json","markdown":"https://secwatch.observer/filing/0001847903-24-000052.md","text":"https://secwatch.observer/filing/0001847903-24-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000052/0001847903-24-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000052/cnta-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:34:04.732747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6afc6a95f2eb50f15017e876f6868b3778e0ec8a","claim":"Centessa Pharmaceuticals plc reported financial results for the fourth quarter and full-year ended December 31, 2023.","evidence_excerpt":"Centessa Pharmaceuticals plc (the \"Company\") announced its financial results for the quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790324000052/0001847903-24-000052-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full-year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}